• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Theravance

Theravance

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, With Asthma and Cystic Fibrosis Leading the Way - Research and Markets

    Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, With Asthma and Cystic Fibrosis Leading the Way - Research and Markets

  2. The Benefits of Diversifying the Funding of a Gold Position

    Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share. The company continues to make progress in each of its programs, namely the addition of a second Phase IIb compound in the Beyond Advair trials and completion ...

  3. Global Fibromyalgia Pipeline Report 2016 - Review of 7 Companies & Drug Profiles - Research and Markets

    Global Fibromyalgia Pipeline Report 2016 - Review of 7 Companies & Drug Profiles - Research and Markets

  4. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.